• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.美国异体造血细胞移植后的社区健康状况和结局。
Cancer. 2021 Feb 15;127(4):609-618. doi: 10.1002/cncr.33232. Epub 2020 Oct 21.
2
Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.改编用于接受异基因造血细胞移植的血液系统恶性肿瘤儿童、青少年和年轻成人的 HCT-CI 定义。
Transplant Cell Ther. 2023 Feb;29(2):123.e1-123.e10. doi: 10.1016/j.jtct.2022.11.019. Epub 2022 Nov 26.
3
The Prevalence of Pretransplant Frailty and Mental Distress in Hematopoietic Cell Transplantation and Association with Clinical Outcomes.造血细胞移植患者移植前衰弱和精神困扰的发生率及其与临床结局的关系。
Transplant Cell Ther. 2024 Sep;30(9):919.e1-919.e9. doi: 10.1016/j.jtct.2024.05.026. Epub 2024 Jun 3.
4
Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.移植后环磷酰胺预防移植物抗宿主病的异基因造血细胞移植后,移植物冷冻保存不影响总体生存率。
Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. doi: 10.1016/j.bbmt.2020.04.001. Epub 2020 Apr 10.
5
Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.造血细胞移植特异性合并症指数(HCT-CI)能否预测移植结局?日本关东地区细胞治疗研究组的一项前瞻性多中心验证研究。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1553-9. doi: 10.1016/j.bbmt.2014.06.005. Epub 2014 Jul 15.
6
ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.ABO血型不匹配与异基因造血细胞移植后非复发死亡率增加有关。
Biol Blood Marrow Transplant. 2015 Apr;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036. Epub 2015 Jan 5.
7
Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.HLA 匹配相关异基因造血干细胞移植中风险评分系统的比较:一项回顾性队列研究。
Turk J Haematol. 2021 Jun 1;38(2):138-144. doi: 10.4274/tjh.galenos.2020.2020.0178. Epub 2020 Jun 16.
8
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.联合造血细胞移植合并症指数和欧洲血液与骨髓移植组评分可更好地对接受低强度异基因造血细胞移植的高危患者进行分层。
Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.
9
Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.供者和受者 Epstein-Barr 病毒血清学状态对异基因造血细胞移植结局的影响:系统评价和荟萃分析。
Ann Hematol. 2021 Mar;100(3):763-777. doi: 10.1007/s00277-021-04428-9. Epub 2021 Jan 25.
10
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.造血细胞移植合并症指数预测能力的前瞻性验证:一项国际血液和骨髓移植研究中心的研究
Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. doi: 10.1016/j.bbmt.2015.04.004. Epub 2015 Apr 7.

引用本文的文献

1
Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.评估移植和CAR-T治疗受者的健康社会决定因素:美国血液与骨髓移植学会生存特别兴趣小组的专家小组建议
Transplant Cell Ther. 2025 Jul 23. doi: 10.1016/j.jtct.2025.07.017.
2
Annual household income and chronic pulmonary conditions in long-term survivors of blood or marrow transplantation: a BMTSS report.血液或骨髓移植长期幸存者的家庭年收入与慢性肺部疾病:一份BMTSS报告。
BMC Pulm Med. 2025 Jul 12;25(1):338. doi: 10.1186/s12890-025-03793-9.
3
Impact of payment source, referral site, and place of residence on outcomes after allogeneic transplantation in Mexico.支付来源、转诊地点及居住地址对墨西哥异基因移植术后结局的影响
World J Transplant. 2024 Jun 18;14(2):91052. doi: 10.5500/wjt.v14.i2.91052.
4
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.真实世界和临床试验中 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤的结局与种族和民族有关。
Blood. 2024 Jun 27;143(26):2722-2734. doi: 10.1182/blood.2023023447.
5
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.社会经济差异对急性髓细胞白血病接受异基因造血细胞移植的成年人结局的影响。
Leukemia. 2024 Apr;38(4):865-876. doi: 10.1038/s41375-024-02172-3. Epub 2024 Feb 22.
6
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.≥1 年异基因造血细胞移植幸存者的长期结局中的种族和社会经济差异:CIBMTR 分析。
Transplant Cell Ther. 2023 Nov;29(11):709.e1-709.e11. doi: 10.1016/j.jtct.2023.07.013. Epub 2023 Jul 22.
7
Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia.西班牙裔和非西班牙裔急性髓系白血病患者的分子特征与预后
EJHaem. 2022 Oct 18;3(4):1231-1240. doi: 10.1002/jha2.589. eCollection 2022 Nov.
8
Social Vulnerability and Risk of Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation.社会脆弱性与异基因造血细胞移植后非复发死亡率的风险。
J Natl Cancer Inst. 2022 Nov 14;114(11):1484-1491. doi: 10.1093/jnci/djac150.
9
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.结构性种族主义是急性髓细胞白血病治疗结果差异的中介因素。
Blood. 2022 Apr 7;139(14):2212-2226. doi: 10.1182/blood.2021012830.
10
Increasing access to allogeneic hematopoietic cell transplant: an international perspective.增加异体造血细胞移植的可及性:国际视角。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):264-274. doi: 10.1182/hematology.2021000258.

本文引用的文献

1
Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis.劣势人群异体移植机会较少:国际血液和骨髓移植研究中心的分析。
Biol Blood Marrow Transplant. 2019 Oct;25(10):2086-2090. doi: 10.1016/j.bbmt.2019.06.012. Epub 2019 Jun 19.
2
Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients.心理社会评估候选者移植 (PACT) 作为一种工具,用于对异基因造血细胞移植受者进行心理和社会评估。
Bone Marrow Transplant. 2019 Sep;54(9):1443-1452. doi: 10.1038/s41409-019-0455-y. Epub 2019 Jan 29.
3
Patient-centered care coordination in hematopoietic cell transplantation.造血细胞移植中以患者为中心的护理协调
Blood Adv. 2017 Aug 22;1(19):1617-1627. doi: 10.1182/bloodadvances.2017008789.
4
Community Risk Score for Evaluating Health Care Disparities in Hematopoietic Cell Transplantation.社区风险评分用于评估造血细胞移植中的医疗保健差异。
Biol Blood Marrow Transplant. 2018 Apr;24(4):877-879. doi: 10.1016/j.bbmt.2017.12.800. Epub 2017 Dec 29.
5
Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.社会经济地位与慢性移植物抗宿主病结局的关系。
Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399. doi: 10.1016/j.bbmt.2017.10.009. Epub 2017 Oct 12.
6
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.在美国,西班牙裔人群在多发性骨髓瘤自体造血细胞移植中的干细胞移植利用率最低:一份CIBMTR报告。
Cancer. 2017 Aug 15;123(16):3141-3149. doi: 10.1002/cncr.30747. Epub 2017 May 4.
7
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理:2017年国际专家小组的欧洲白血病网络(ELN)建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
8
Utility of Ecological Risk Factors for Evaluation of Transplant Center Performance.用于评估移植中心绩效的生态风险因素的效用
Am J Transplant. 2017 Mar;17(3):617-621. doi: 10.1111/ajt.14074. Epub 2016 Oct 31.
9
Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study.异基因造血细胞移植对患者及其家庭超过2年的经济影响:一项多中心试点研究的结果
Bone Marrow Transplant. 2016 Sep;51(9):1233-40. doi: 10.1038/bmt.2016.103. Epub 2016 Apr 18.
10
Outcomes in endocrine cancer surgery are affected by racial, economic, and healthcare system demographics.内分泌癌手术的结果受到种族、经济和医疗保健系统人口统计学特征的影响。
Laryngoscope. 2016 Mar;126(3):775-81. doi: 10.1002/lary.25606. Epub 2015 Sep 15.

美国异体造血细胞移植后的社区健康状况和结局。

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

机构信息

Blood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

出版信息

Cancer. 2021 Feb 15;127(4):609-618. doi: 10.1002/cncr.33232. Epub 2020 Oct 21.

DOI:10.1002/cncr.33232
PMID:33085090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7855526/
Abstract

BACKGROUND

The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.

METHODS

This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.

RESULTS

The median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.

CONCLUSIONS

Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.

摘要

背景

社区因素与造血细胞移植(HCT)后的结果之间的关联尚未得到全面描述。本研究使用县健康排名和路线图(CHRR)和国际血液和骨髓移植研究中心(CIBMTR),评估了社区健康状况对异基因 HCT 结果的影响。

方法

本研究纳入了 2014 年至 2016 年期间,170 个美国中心向 CIBMTR 报告的 18544 例成人异基因 HCT 受者。社会人口统计学、环境和社区指标源自 CHRR,创建了一个综合社区风险评分,并为每位患者(患者社区风险评分 [PCS])和移植中心(中心社区风险评分 [CCS])分配评分。较高的分数表示社区健康状况较差。研究了 PCS 和 CCS 对异基因 HCT 后患者结局的影响。

结果

中位年龄为 55 岁(范围,18-83 岁)。中位 PCS 为-0.21(范围,-1.37 至 2.10;标准差 [SD],0.42),中位 CCS 为-0.13(范围,-1.04 至 0.96;SD,0.40)。在多变量分析中,PCS 较高与生存不良相关(每增加 1 SD 的风险比 [HR],1.04;99%CI,1.00-1.08;P=.0089)。在血液系统恶性肿瘤中,较高的 PCS 与生存不良的趋势相关(HR,1.04;99%CI,1.00-1.08;P=.0102);较高的 PCS 与较高的非复发死亡率(NRM;HR,1.08;99%CI,1.02-1.15;P=.0004)相关。CCS 与生存、复发或 NRM 无显著相关性。

结论

居住在社区健康状况较差的县的患者,由于异基因 HCT 后 NRM 风险增加,生存状况较差。移植中心所在社区的健康状况与异基因 HCT 结果之间没有关联。